Scholarlink

Background <p>Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritic papules with redness and/or hyperpigmentation. Topical therapy may be considered a safe and efficacious approach for mild AD, and as a complementary therapy for moderate and severe AD.</p> Objectives <p>To evaluate the efficacy and safety of tapinarof cream, a topical aryl hydrocarbon receptor agonist in patients with AD.</p> Methods <p>Pubmed, Embase, and Cochrane were systematically searched for randomized clinical trials (RCTs) that compared tapinarof cream versus vehicle in patients with AD. Risk ratios (RRs) were computed for binary endpoints, with 95% confidence intervals (95% CIs). Statistical significance was defined as p-value &lt; 0.05.</p> Results <p>A total of 5 RCTs and 1,165 patients were included, with 755 (64.8%) patients in the tapinarof group. Compared with the vehicle group, patients assigned to tapinarof had a greater achievement in an Investigator’s Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) (RR 2.42; 95% CI 1.73 to 3.38; p &lt; 0.001), and 75% or greater improvement in Eczema Area and Severity Index (EASI) score (RR 2.65; 95% CI 2.14 to 3.29; p &lt; 0.001). However, patients in the tapinarof group had significantly higher rates of adverse events (RR 1.58; 95% CI 1.34 to 1.86; p &lt; 0.001), including folliculitis (RR 6.21; 95% CI 2.49 to 15.50; p &lt; 0.001), and headache (RR 3.24; 95% CI 1.15 to 9.06; p = 0.025) than with vehicle.</p> Conclusion <p>This meta-analysis concluded that the use of tapinarof cream was effective and well tolerated in patients with AD. Further studies evaluating the long-term efficacy of tapinarof cream are needed.</p> <p><i>PROSPERO number:</i> CRD42024592110.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Tapinarof cream in the treatment of atopic dermatitis in children and adults a systematic review and meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月27日

查看全文
  • Ana Clara Felix de Farias Santos,
  • Fernanda Valeriano Zamora,
  • Deivyd Vieira Silva Cavalcante,
  • Beatriz Ximenes Mendes,
  • Gabriela Oliveira Gonçalves Molino,
  • Lorhayne Kerley Capuchinho Scalioni Galvao,
  • Nicole dos Santos Pimenta,
  • Belisa Brunow Ventura Biavatti,
  • João Pedro Costa Esteves Almuinha Salles,
  • Andres Villca Zamora

摘要

Background

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritic papules with redness and/or hyperpigmentation. Topical therapy may be considered a safe and efficacious approach for mild AD, and as a complementary therapy for moderate and severe AD.

Objectives

To evaluate the efficacy and safety of tapinarof cream, a topical aryl hydrocarbon receptor agonist in patients with AD.

Methods

Pubmed, Embase, and Cochrane were systematically searched for randomized clinical trials (RCTs) that compared tapinarof cream versus vehicle in patients with AD. Risk ratios (RRs) were computed for binary endpoints, with 95% confidence intervals (95% CIs). Statistical significance was defined as p-value < 0.05.

Results

A total of 5 RCTs and 1,165 patients were included, with 755 (64.8%) patients in the tapinarof group. Compared with the vehicle group, patients assigned to tapinarof had a greater achievement in an Investigator’s Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) (RR 2.42; 95% CI 1.73 to 3.38; p < 0.001), and 75% or greater improvement in Eczema Area and Severity Index (EASI) score (RR 2.65; 95% CI 2.14 to 3.29; p < 0.001). However, patients in the tapinarof group had significantly higher rates of adverse events (RR 1.58; 95% CI 1.34 to 1.86; p < 0.001), including folliculitis (RR 6.21; 95% CI 2.49 to 15.50; p < 0.001), and headache (RR 3.24; 95% CI 1.15 to 9.06; p = 0.025) than with vehicle.

Conclusion

This meta-analysis concluded that the use of tapinarof cream was effective and well tolerated in patients with AD. Further studies evaluating the long-term efficacy of tapinarof cream are needed.

PROSPERO number: CRD42024592110.